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Adenine nucleotides represent crucial immunomodulators in the extracellular envi-
ronment. The ectonucleotidases CD39 and CD73 are responsible for the sequen-
tial catabolism of ATP to adenosine via AMP, thus promoting an anti- inflammatory 
milieu induced by the “adenosine halo”. AMPD2 intracellularly mediates AMP 
deamination to IMP, thereby both enhancing the degradation of inflammatory ATP 
and reducing the formation of anti- inflammatory adenosine. Here, we show that 
this enzyme is expressed on the surface of human immune cells and its predomi-
nance may modify inflammatory states by altering the extracellular milieu. Surface 
AMPD2 (eAMPD2) expression on monocytes was verified by immunoblot, surface 
biotinylation, mass spectrometry, and immunofluorescence microscopy. Flow cy-
tometry revealed enhanced monocytic eAMPD2 expression after TLR stimulation. 
PBMCs from patients with rheumatoid arthritis displayed significantly higher levels 
of eAMPD2 expression compared with healthy controls. Furthermore, the product of 
AMPD2— IMP— exerted anti- inflammatory effects, while the levels of extracellular 
adenosine were not impaired by an increased eAMPD2 expression. In summary, our 
study identifies eAMPD2 as a novel regulator of the extracellular ATP- adenosine 
balance adding to the immunomodulatory CD39- CD73 system.
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1 |  INTRODUCTION
In recent years, extracellular adenosine (eADO) has emerged 
as an important factor in the pathogenesis of immune- 
mediated and neoplastic diseases.1,2 eADO is mainly provided 
by the degradation of extracellular ATP (eATP) through the 
subsequent action of different ectonucleotidases.3 The pro-
cess of enzymatic ADO production is subdivided into two 
interacting pathways: the more prominent canonical pathway 
and the alternative pathway. The canonical pathway consists 
of the rate- limiting ectonucleoside triphosphate diphospho-
hydrolase- 1 (CD39) and the ecto- 5'- nucleotidase (CD73). 
While CD39 catalyzes the dephosphorylation of ATP and 
ADP to AMP, CD73 mediates the phosphorolytic cleavage 
of the latter, thereby producing ADO.4 On the other hand, the 
alternative pathway involves the conversion of extracellular 
NAD+ to ADP ribose by CD38, followed by AMP produc-
tion by CD203a/PC- 1.5,6 These pathways of ADO genera-
tion are completed by an additional ectoenzyme— adenosine 
deaminase— that terminates ADO action by deamination to 
inosine.7 Beyond ectoenzyme activity, extracellular adenine 
nucleotide levels are determined by cellular uptake and re-
lease via channel proteins and nucleoside transporters.8- 11
Extracellular purine metabolites signal via two major 
classes of receptors: P2 receptors mediate the action of purine 
nucleotides like ATP. The P1 receptor family, on the other 
hand, consists of four ADO receptors (A1R, A2AR, A2BR, 
A3R) that signal via different G- proteins.12 Purinergic recep-
tors are expressed ubiquitously throughout different tissues 
and elicit a myriad of effects.13 Our work focuses on the role 
of adenine nucleotides in the context of inflammation.
The increasing understanding of the regulation of eADO 
production as well purinergic signaling has enhanced the de-
velopment of therapeutic concepts involving adenosinergic 
pathways.1,12,14,15 eATP is released from cells under condi-
tions of stress and inflammation, thereby functioning as an 
alarm in provoking a pro- inflammatory reaction.16- 23 In con-
trast, eADO represents a potent anti- inflammatory agent.24- 33 
Anti- inflammatory effects of eADO have mainly been at-
tributed to the activation of A2R and A3R and agonists of 
these receptors are currently being evaluated as therapeutic 
agents to treat inflammatory conditions.34- 38
Besides ADO receptors, leukocytes are also equipped with 
ectonucleotidases permitting a regulation of the inflamma-
tory environment by both ATP breakdown and ADO genera-
tion. CD39 and CD73 are differentially expressed on distinct 
immune cell subsets. While CD39 expression is present in the 
majority of neutrophils, dendritic cells (DC), monocytes and 
B lymphocytes (BL) as well as a subset of regulatory T cells 
(Treg), CD73 is expressed by DCs, BLs, cytotoxic T cells, 
and several non- immune cells like mesenchymal stromal cells 
(MSC) and endothelial cells.39- 46 In contrast, only a small subset 
of CD4+ T helper (TH) cells is characterized by CD39 or CD73 
expression.47 Recent research has revealed a dysregulation of 
the adenosinergic system in many autoimmune diseases.48- 51
Conversely, enhanced tumor growth has been ascribed to a 
surplus of anti- inflammatory eADO.52- 55 Therefore, blocking 
eADO generation or ADO receptor signaling might eliminate 
the protective “adenosine halo” and restore an environment 
permitting an effective anti- tumor immune response.2,12,56 
Recent approaches examining this therapeutic concept have 
yielded promising results.57- 61 These findings demonstrate 
the clinical relevance of adenosinergic signaling and high-
light the importance of a deep understanding of extracellular 
purine metabolism.
In this context, we noticed that the ensemble of ectoen-
zymes implicated in the regulation of extracellular adenine 
nucleotides is incomplete compared with the complex net-
work of reactions involved in intracellular purine metab-
olism.62 While AMP deamination substantially modifies 
cytosolic purine content, it has hitherto not been recognized 
as an essential reaction in the extracellular space. Although 
previous studies have reported attachment of AMP deami-
nases (AMPDs) to the muscle surface and the inner erythro-
cyte membrane,63- 66 surface expression of AMPD in human 
leukocytes has not yet been described. AMPDs are respon-
sible for the conversion of AMP to IMP by hydrolyzing the 
amino group from the 6- position of the adenine nucleotide 
ring. In contrast to adenine nucleot(s)ides, the immunomod-
ulatory role of IMP in the extracellular space remains un-
clear. AMP deamination facilitates the removal of AMP that 
accumulates in states of energy depletion. By increasing the 
ATP:AMP ratio, AMPDs promote energy yield from ATP 
hydrolysis.62,67- 69 At the same time, AMPDs compete with 
5′- nucleotidases for AMP supply, thereby impeding the for-
mation of anti- inflammatory ADO. Conversely, loss of func-
tion mutations in the AMPD genes as well as the development 
of AMPD inhibitors have shown that reduced AMP deamina-
tion is associated with an increase in ADO levels.70- 72 We hy-
pothesized that this principle might be equally relevant to the 
modification of extracellular purine levels under inflamma-
tory conditions. Therefore, we examined AMPD expression 
on the outer plasma membrane of immune cells.
Here, we demonstrate that AMPD2 is expressed on the 
cell surface of primary human leukocytes and may func-
tion as a novel regulator of extracellular purine metabolism, 
thereby modifying the ATP- adenosine balance controlled by 
the CD39- CD73 ectonucleotidase system (Figure 1).
2 |  MATERIALS AND METHODS
2.1 | Subjects
Fifteen patients with a diagnosis of rheumatoid arthri-
tis (RA) were recruited as part of the Charité Rh- GIOP 
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study at the Department of Rheumatology and Clinical 
Immunology at Charité- Universitätsmedizin Berlin, 
Germany. Patients with active disease and in remission 
were considered for the study. Patients were included ir-
respective of their current immunosuppressive therapy. 
Thirteen healthy donors were matched for sex and age. The 
study was performed in accordance with the Declaration of 
Helsinki and ethical approval was obtained from the local 
ethics committee (Charité- Universitätsmedizin Berlin, 
approval number EA1/207/17). All participants gave in-
formed written consent.
2.2 | Preparation of peripheral blood 
leukocytes and magnetic cell separation
Peripheral venous blood was collected in lithium hepa-
rin tubes. Isolation of polymorphonuclear leukocytes was 
preceded by red blood cell lysis using erythrocyte lysis 
buffer (0.01  M KHCO3, 0.155  M NH4Cl, 0.1  mM EDTA, 
pH 7.5). CD15+ neutrophil granulocytes were purified by 
magnetic activated cell sorting (MACS) with anti- CD15- 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany, 
Cat# 130- 094- 530, RRID:AB_2814656). Peripheral blood 
mononuclear cells (PBMCs) were isolated from the blood 
samples by Ficoll- Paque PLUS (GE Healthcare, Chicago, 
Illinois) density gradient centrifugation. CD14+ monocytes 
were isolated from PBMCs by MACS using anti- CD14- 
microbeads provided by Miltenyi Biotec (Cat# 130- 050- 201, 
RRID:AB_2665482). Cell preparations were performed ac-
cording to the manufacturer's instructions. Purity of isolated 
CD14+ monocytes and CD15+ neutrophils exceeded 97% as 
verified by flow cytometry (Figure S1B+C).
2.3 | Chemicals and reagents
Dulbecco's Modified Eagle Medium (DMEM), Roswell 
Park Memorial Institute 1640 Medium (RPMI), MCDB 131 
Medium, penicillin, streptomycin, and L- glutamine were 
obtained from Gibco (Thermo Fisher Scientific, Waltham, 
Massachusetts). Fetal calf serum (FCS), human AB serum, 
β- mercaptoethanol (2- ME), Accutase solution, brefeldin A 
(BFA), monensin (MN), lipopolysaccharide (LPS), flagellin 
(FliC), phytohemagglutinin- L (PHA- L), Phorbol 12- myristate 
13- acetate (PMA), ionomycin, dexamethasone (Dex), hy-
drocortisone, Epidermal Growth Factor (EGF), ATP, ADO, 
IMP, and inosine were purchased from Sigma- Aldrich (St. 
Louis, Missouri). Miltenyi Biotec provided Poly (I:C) and 
ODN 2006. Pam3CSK4, FSL- 1, and Resiquimod (R848) 
were purchased from Tocris (Bristol, United Kingdom).
2.4 | Antibodies
Staining for flow cytometry was performed using an-
tibodies against AMPD2 (unconjugated, 1:50, rabbit 
polyclonal, Thermo Fisher Scientific, Cat# PA5- 26127, 
RRID:AB_2543627), CD3 (Brilliant Violet 510, 1:20, 
OKT3, BioLegend, San Diego, California, Cat# 317332, 
RRID:AB_2561943), CD3 (Alexa Fluor 594, 1:20, UCHT1, 
DRFZ, Cat# UCHT1, RRID:AB_2619695), CD4 (APC- Vio 
770, 1:10, M- T321, Miltenyi Biotec, Cat# 130- 100- 357, 
RRID:AB_2657994), CD8 (Alexa Fluor 647, 1:200 and Alexa 
Fluor 700, 1:1600, GN11/134D7, DRFZ), CD14 (FITC, 
1:400, TM1, DRFZ), CD14 (Brilliant Violet 650, 1:20, M5E2, 
BioLegend, Cat# 301835, RRID:AB_11204241), CD15 
(FITC, 1:10, VIMC6, Miltenyi Biotec, Cat# 130- 081- 101, 
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RRID:AB_244217), CD16 (APC/Cyanin7, 1:50, 3G8, 
BioLegend, Cat# 302018, RRID:AB_314218), CD19 
(PerCP/Cyanine5.5, 1:100, HIB19, BioLegend, Cat# 302230, 
RRID:AB_2073119), CD25 (Brilliant Violet 785, 1:20, BC96, 
BioLegend, Cat# 302637, RRID:AB_11219197), CD39 
(APC, 1:100, REA739, Miltenyi Biotec, Cat# 130- 110- 789, 
RRID:AB_2657891), CD45 (FITC, 1:20, HI30, BioLegend, 
Cat# 304006, RRID:AB_314394), CD45RA (Pacific Orange, 
1:50, 4G11, DRFZ), CD73 (Brilliant Violet 421, 1:50, AD2, 
BioLegend, Cat# 344008, RRID:AB_11204424), CD127 
(PE, 1:25, REA614, Miltenyi Biotec, Cat# 130- 109- 514, 
RRID:AB_2654831), CD127 (FITC, 1:10, MB15- 18C9, 
Miltenyi Biotec, Cat# 130- 098- 093, RRID:AB_2659850), 
CCR4 (Brilliant Violet 605, 1:20, L291H4, BioLegend, Cat# 
359418, RRID:AB_2562483), CCR6 (APC, 1:20, REA190, 
Miltenyi Biotec, Cat# 130- 100- 373, RRID:AB_2655933), 
and CXCR3 (PE- Vio 770, 1:50, REA232, Miltenyi Biotec, 
Cat# 130- 101- 382, RRID:AB_2655739). Goat anti- rabbit IgG 
(PE, 1:200, Invitrogen, Cat# P2771MP, RRID:AB_221651), 
streptavidin (PE, 1:200, Life Technologies, Cat# S866) 
and streptavidin (APC/Cyanine7, 1:300, BioLegend Cat# 
405208) were used as secondary reagents. The following iso-
type controls were utilized to verify the staining: rabbit IgG 
(unconjugated, 1:125, Invitrogen, Carlsbad, California, Cat# 
02- 6102, RRID:AB_2532938), REA Control (S) (APC, 1:10, 
Miltenyi Biotec, Cat# 130- 113- 434, RRID:AB_2733447), 
and Mouse IgG1, κ Isotype Ctrl Antibody (Brilliant 
Violet 421, 1:50, MOPC- 21, BioLegend, Cat# 400157, 
RRID:AB_10897939). The following antibodies were used 
for immunofluorescence microscopy: anti- AMPD2 anti-
body (unconjugated, 1:50, rabbit polyclonal, Thermo Fisher 
Scientific, Cat# PA5- 26127, RRID:AB_2543627) and goat 
anti- rabbit IgG (Alexa Fluor Plus 488, 1:500, Thermo Fisher 
Scientific, Cat# A32731, RRID:AB_2633280). Antibodies 
against AMPD2 (1:500, QQ13, SCBT, Dallas, Texas, Cat# 
sc- 100504, RRID:AB_2258261), beta Actin (1:10  000, 
BA3R, Invitrogen, Cat# MA5- 15739, RRID:AB_10979409), 
glyceraldehyde 3- phosphate dehydrogenase (GAPDH) 
(1:100, 6C5, Merck Millipore, Burlington, Massachusetts, 
Cat# MAB374, RRID:AB_2107445), alpha Tubulin 
(100  ng/mL, rabbit polyclonal, abcam, Cambridge, United 
Kingdom, Cat# ab4074, RRID:AB_2288001), pan Cadherin 
(1:500, CH- 19, abcam, Cat# ab6528, RRID:AB_305544), 
CD14 (Biotin, 1:50, TM1, DRFZ), lamin B1 (1:200, B- 10, 
SCBT, Cat# sc- 374015, RRID:AB_10947408), cytochrome 
b (1:200, SCBT, Cat# sc- 11436, RRID:AB_2088887), cal-
reticulin (1:2000, Thermo Fisher Scientific, Cat# PA1- 902A, 
RRID:AB_2069607), mouse IgG (HRP, 1:10 000, Promega, 
Madison, Wisconsin, Cat# W4021, RRID:AB_430834), 
rabbit IgG (HRP, 1:10  000, Promega, Cat# W4011, 
RRID:AB_430833), chicken IgY (HRP, 1:5000, Thermo 
Fisher Scientific Cat# A16054, RRID:AB_2534727) and 
streptavidin (HRP, 1:1000, R&D Systems, Minneapolis, 
Minnesota, Cat# DY998) were used for western blot analy-
sis. Mouse monoclonal (2 µL, QQ13, SCBT, Cat# sc- 100504, 
RRID:AB_2258261) and rabbit polyclonal (3  µL, Thermo 
Fisher Scientific, Cat# PA5- 26127, RRID:AB_2543627) 
anti- AMPD2 antibodies were applied to realize immunopre-
cipitation (IP) of AMPD2, while mouse IgG1 (1:10, 2  µL, 
Invitrogen, Cat# 02- 6100, RRID:AB_2532935) and rabbit 
IgG (1,2 µL, Invitrogen, Cat# 02- 6102, RRID:AB_2532938) 
served as isotype controls.
2.5 | Cell culture
Human embryonic kidney 293 (HEK293) cells (Cat# 
CRL- 1573, RRID:CVCL_0045) were purchased from 
ATCC (Manassas, Virginia) and cultured in DMEM sup-
plemented with 10% (v/v) FCS. Jurkat (ATCC, Cat# TIB- 
152, RRID:CVCL_0367), THP- 1 (ATCC, Cat# TIB- 202, 
RRID:CVCL_0006) and U- 937 (ATCC, Cat# CRL- 1593, 
RRID:CVCL_0007) cells were cultured in RPMI sup-
plemented with 10% (v/v) FCS. Human microvascular en-
dothelial cells- 1 (HMEC- 1) (ATCC, Cat# CRL- 10636, 
RRID:CVCL_0307) were cultured in MCDB 131 Medium 
supplemented with 25% (v/v) FCS, 2  mM L- glutamine, 
10 ng/mL EGF and 0.3 µg/mL hydrocortisone. Human pri-
mary immune cells were cultured in RPMI supplemented 
with 10% (v/v) human AB serum. 100  U/mL penicillin, 
100 µg/mL streptomycin and 50 µM 2- ME were added to all 
media used. Cells were incubated in a humidified atmosphere 
at 5% CO2 and approximately 18% O2. Hypoxia was estab-
lished by placing the cells in a hypoxic chamber (Binder) at 
1% O2. Incubation with either 1 µg/mL Pam3CSK4, 10 µg/
mL Poly (I:C), 1 µg/mL LPS, 100 ng/mL FliC, 1 µg/mL FSL- 
1, 1 µg/mL R848, 0.5 µM ODN 2006, 5 µg/mL PHA- L, or 
10 ng/mL PMA and 1 µg/mL ionomycin was performed as 
indicated to provoke immunostimulation. Inhibition of the 
golgi apparatus was achieved by incubation with 1  µg/mL 
BFA or 0.5 µg/mL MN. Dex was applied at concentrations 
of 10−5 M or 10−8 M as indicated while methotrexate (MTX) 
(medac, Wedel, Germany) was utilized at 0.8 µM. Adherent 
cells were detached with the help of Accutase solution for 
5 minutes at 37°C.
2.6 | Transfection of HEK293 cells with 
short hairpin RNA (shRNA)
Bacterial stocks containing shRNA plasmids cloned into 
the pLKO.1 puro vector were purchased from Sigma- 
Aldrich (MISSION shRNA). Hairpin sequences are pro-
vided in Table 1. The empty lentiviral backbone of pLKO.1 
puro was provided by Bob Weinberg (Addgene plasmid 
#8453; http://n2t.net/addge ne:8453; RRID:Addgene_8453) 
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whereas the plasmid containing scrambled shRNA was 
a gift from David Sabatini (Addgene plasmid #1864; 
http://n2t.net/addge ne:1864; RRID:Addgene_1864).73,74 
Bacterial colonies were cultured according to the manufac-
turer's instructions and plasmid DNA was prepared using 
NucleoBond Xtra EF (Macherey- Nagel, Düren, Germany). 
HEK293 cells were transfected with 30 µg of each plasmid 
to achieve transient knockdown of AMPD2.
2.7 | Lentivirus production and 
transduction of HEK293 and U- 937 cells
Viral particles were produced by co- transfecting HEK293 
cells with packaging plasmids pPAX2 and pVSVG by means 
of calcium phosphate precipitation. Viral supernatants were 
harvested after 48 hours and supplemented with 10 µg/mL 
polybrene (Sigma- Aldrich). Infection of HEK293 and U- 937 
cells was achieved by centrifugation for 2  hours at 700  g 
and 32°C. Successfully transduced cells were selected for at 
least 10 days by adding 1 µg/mL puromycin (InvivoGen, San 
Diego, California) to the culture medium.
2.8 | Sample preparation for 
protein analysis
Whole cell protein was prepared by lysing 106 cells in 20 µL 
Laemmli sample buffer (Bio- Rad, Hercules, California, Cat# 
1610747). IP lysis buffer (10 mM Tris HCl pH 7.5, 10 mM 
NaCl, 2 mM EDTA, 0.1% (v/v) Triton X- 100, 1 mM PMSF, 
2  µg/mL aprotinin) supplemented with protease and phos-
phatase inhibitor (Thermo Fisher Scientific, Cat# 78440) 
yielded whole cell lysates suitable for IP: 10  ×  106 cells 
were lyzed in 300  µL IP lysis buffer for 5  minutes on ice. 
12  µL 3  M NaCl were added for another 10  minutes prior 
to centrifugation for 15 minutes at 16 000 g and 4°C, yield-
ing a clear supernatant. Cytosolic and membrane fractions 
were prepared using the Mem- PER Plus Membrane Protein 
Extraction Kit (Thermo Fisher Scientific, Cat# 89842). 
Additionally, surface protein enriched samples were obtained 
by surface biotinylation followed by streptavidin- based pull- 
down (Pierce Cell Surface Protein Isolation Kit, Thermo 
Fisher Scientific). The manufacturer's protocols were fol-
lowed for both procedures. In order to concentrate cytosolic 
and membrane fractions prior to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS- PAGE), the lysates were 
concentrated using Amicon Ultra- 0.5 mL Centrifugal Filters 
(50K, Merck Millipore Ltd., Ireland). Prior to IP or SDS- 
PAGE, respectively, protein concentrations of the lysates 
were determined by bicinchoninic acid assay (BCA assay, 
Interchim, Montluçon, France) and equal protein amounts 
were applied to the subsequent procedure. Before IP, the 
lysates were precleared with 20 µL protein A/G plus agarose 
(SCBT, Cat# sc- 2003, RRID:AB_10201400) for 30 minutes 
at 4°C. IP of AMPD2 was performed by incubating 1  mL 
lysate with either antibody against AMPD2 or isotype control 
overnight. Pull- down was achieved by adding 20 µL protein 
A/G plus agarose and four 5- minute washing steps with 1 mL 
IP buffer (0.15  M NaCl, 0.05  M Tris- HCl pH 8, 1% (v/v) 
NP40) supplemented with protease and phosphatase inhibitor 
(Thermo Fisher Scientific, Cat# 78440) followed by centrifu-
gation at 1000 g for one minute. Agarose pellets were pre-
pared for SDS- PAGE by adding 6.5 µL 4× Laemmli sample 
buffer (Bio- Rad, Cat# 1610747) or directly digested for mass 
spectrometric analysis (see Protein Digest below).
2.9 | Western blot analysis
Samples were separated by SDS- PAGE and subsequently 
blotted onto PVDF membranes (Merck Millipore). PVDF 
membranes were block with 5% (w/v) nonfat dry milk 
(AppliChem GmbH, Darmstadt, Germany) in TBS/0.05% 
Tween 20 (Sigma- Aldrich) for 90  minutes followed by 
three 10- minute washing steps with TBS/0.05% Tween 20. 
Protein detection was accomplished with the aforementioned 
antibodies diluted in TBS/0.05% Tween 20: the membranes 
were incubated with the primary antibody for 2 hours at room 
temperature (RT) or overnight at 4°C. The secondary anti-
body was added for 1 hour at RT. Each step was followed 
by three 10- minute washing steps with TBS/0.05% Tween 









6 of 25 |   EHLERS Et aL.
20. Visualization was accomplished by enzymatic chemilu-
minescence (PerkinElmer, GE Healthcare) in an ImageQuant 
LAS 4000 imager (GE Healthcare).
2.10 | Protein digest
Antibody pull- down samples were processed for mass spec-
trometry as follows: Dry beads were resuspended in 20 µL 
urea buffer (6 M urea, 2 M thiourea, 10 mM HEPES, pH 8.0) 
and reduced for 30 minutes at RT in 12 mM dithiothreitol 
solution, followed by alkylation by 40 mM chloroacetamide 
for 20 minutes in the dark at RT. The samples were first di-
gested using 1 µg endopeptidase LysC (Wako, Osaka, Japan) 
for 4 hours, followed by dilution in 4 volumes of 50 mM am-
monium bicarbonate buffer (pH  =  8.5) and digestion with 
1 µg sequence- grade trypsin (Promega) for 16h. The diges-
tion was stopped by acidifying each sample to pH < 2.5 by 
adding trifluoroacetic acid solution (final concentration 1%). 
The peptides were extracted and desalted using the StageTip 
protocol.75 Samples from streptavidin pull- down experiments 
were processed using the SP3 protein clean- up and digestion 
protocol.76 Peptides were collected, extracted, and desalted 
using the StageTip protocol.75 Proteins from total cell lysate, 
cytosolic and membrane fraction (input samples) were ex-
tracted with 6 M Guanidinium chloride/50 mM ammonium 
bicarbonate buffer (pH = 8.5) and reduced for 30 minutes at 
RT in 12 mM dithiothreitol solution, followed by alkylation 
by 40 mM chloroacetamide for 20 minutes in the dark at RT. 
The samples were digested and desalted as described above.
2.11 | LC- MS/MS analyses
For LC- MS/MS analyses peptides were eluted with 80% 
Acetonitrile/0.1% formic acid, dried and resolved in 3% 
acetonitrile/0.1% formic acid. Peptides were separated on a 
reversed- phase column (20 cm fritless silica microcolumns 
with an inner diameter of 75 µm, packed with ReproSil- Pur 
C18- AQ 1.9  µm resin (Dr Maisch GmbH, Ammerbuch- 
Entringen, Germany)) with a 250  nL/min flow rate of in-
creasing Buffer B concentration (from 2% to 60%) on a 
High Performance Liquid Chromatography (HPLC) system 
(Thermo Fisher Scientific). A 90- minute gradient was ap-
plied for antibody- based and streptavidin- based pull- down 
samples, whereas a 202- minute gradient was applied for input 
samples. Peptides from pull- down samples were analyzed 
on a Q Exactive Plus or HF- X Hybrid Quadrupole- Orbitrap 
instrument (Thermo Fisher Scientific). Input sample meas-
urements were performed with an Orbitrap Fusion Tribrid 
instrument (Thermo Fisher Scientific). The Q Exactive Plus 
instrument was run in data dependent mode selecting the Top 
10 most intense ions in the MS full scans, selecting ions from 
350 to 2000 m/z, using 70K resolution with a 3 × 106 ion count 
target and 50 ms injection time. Tandem MS was performed 
by isolation at 1.6 m/z with the quadrupole, HCD fragmenta-
tion with normalized collision energy of 26 and resolution of 
17.5K. The MS2 ion count target was set to 5 × 104 with a 
maximum injection time of 250 ms For measurements with 
the HF- X instrument the Top 20 most intense ions in the MS 
full scans from 350 to 1800  m/z were selected, using 60K 
resolution with a 3 × 106 ion count target and 10 ms injection 
time. Tandem MS was performed by isolation at 1.3 m/z with 
the quadrupole, HCD fragmentation with normalized colli-
sion energy of 27 and resolution of 15K. The MS2 ion count 
target was set to 1 × 105 with a maximum injection time of 
22 ms The Orbitrap Fusion Tribrid instrument was run in data 
dependent mode selecting the top 20 most intense ions in the 
MS full scans, selecting ions from 350 to 2000  m/z, using 
60K resolution with a 4 × 105 ion count target and 50 ms 
injection time. Tandem MS was performed by isolation at 
0.7 m/z with the quadrupole, HCD fragmentation with nor-
malized collision energy of 32 and resolution of 15K. The 
MS2 ion count target was set to 5 × 104 with a maximum in-
jection time of 250 ms For all measurements only precursors 
with charge state 2- 7 were sampled for MS2. The dynamic 
exclusion duration was set to 30  seconds with a 10  ppm 
tolerance around the selected precursor and its isotopes. 
Data were analyzed using the MaxQuant software package 
(v1.6.0.1). The internal Andromeda search engine was used 
to search MS2 spectra against a decoy human UniProt da-
tabase (HUMAN.2017, HUMAN.2019) containing forward 
and reverse sequences. The search included variable modifi-
cations of methionine oxidation and N- terminal acetylation, 
deamidation (N and Q) and fixed modification of carbami-
domethyl cysteine. Minimal peptide length was set to seven 
amino acids and a maximum of 3 missed cleavages was al-
lowed. The FDR (false discovery rate) was set to 1% for pep-
tide and protein identifications. Unique and razor peptides 
were considered for quantification. Retention times were 
recalibrated based on the built- in nonlinear time- rescaling 
algorithm. MS2 identifications for technical replicates were 
transferred between runs with the “Match between runs” 
option. iBAQ values and LFQ (label- free quantification) in-
tensities were calculated using the in- built algorithms. The 
resulting text files were filtered to exclude reverse database 
hits, potential contaminants, and proteins only identified by 
site. The mass spectrometry proteomics data have been de-
posited to the ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD022350.77
2.12 | Flow cytometry
Staining for flow cytometry was performed on ice. Dead 
cell removal (Miltenyi Biotec) was performed prior to 
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the staining as indicated. The cells were resuspended in 
PBS/0.5% BSA/0.05% sodium azide (PBA). 10% (v/v) human 
IgG (Kiovig [100 mg/mL, 1:2 dilution], Baxter AG, Wien, 
Austria) was added to block unspecific binding of Fc recep-
tors. Specificity was ensured by incubating the cells with 25- 
fold excess unconjugated antibody for 10 minutes prior to the 
staining procedure to block binding of the primary antibody. 
Cells were incubated with a combination of the aforemen-
tioned antibodies for 10 minutes followed by two 3- minute 
washing steps with PBA at 300 g and 4°C. Where applicable, 
cells were subsequently incubated with a secondary antibody 
for 10 minutes and washed as before. Apoptotic cells were 
identified using annexin V (Cy5, 1:100, BD, Franklin Lakes, 
New Jersey, Cat# 559934, RRID:AB_2869267), while 7- 
AAD (1:100, BD, Cat# 559925, RRID:AB_2869266) and 
DAPI (1  µg/mL, Sigma- Aldrich) where applied to exclude 
dead cells. Cells were fixed and permeabilized with −20°C 
cold 90% (v/v) methanol to complete intracellular stainings. 
The samples were measured using a MACSQuant Analyzer 
10 (Miltenyi Biotec) and an LSRFortessa cell analyzer (BD) 
and analyzed with FlowJo software (version 7.6.4 and 10.7.1, 
BD). eAMPD2, CD39 and CD73 expression was recorded by 
determining geometric mean fluorescence intensity (gMFI). 
Results are provided as the ratio (r gMFI) of staining to either 
block or secondary antibody control. Lymphocyte subsets 
were analyzed as follows: CD4+ T cell subsets were sub-
divided into Type 1 helper (TH1) cells, Type 2 helper (TH2) 
cells and IL- 17- producing T helper (TH17) cells. TH1 cells 
were identified by the expression of CXCR3 in the absence of 
CCR4 and CCR6. TH2 cells were defined as CCR4+CXCR3- 
CCR6- , while TH17 cells co- expressed CCR4 and CCR6 in 
the absence of CXCR3. CD4+CD25+CD127low cells were 
defined as regulatory T cells (Treg).78 Cytotoxic T cells 
and B cells were identified by the expression of CD8 and 
CD19, respectively. Monocytes were subanalyzed accord-
ing to CD14 and CD16 surface expression as follows: clas-
sical (CD14hi, CD16- ), intermediate (CD14hi, CD16+) and 
non- classical (CD14low, CD16hi).79 The gating strategy is de-
picted in Figure S1A,E.
2.13 | Immunofluorescence microscopy
Human PBMCs were seeded onto 8- well chamber slides 
directly after isolation, while U- 937 cells were stained in 
a 48- well plate and subsequently centrifuged onto a glass 
slide at 500  g for 1  minute with the help of a Cytospin 4 
cytocentrifuge (Thermo Fisher Scientific). The cells were 
fixed with 4% paraformaldehyde for 8 minutes followed by 
three 3- minute washing steps with PBS. In order to achieve 
intracellular staining the cells were permeabilized prior to 
the staining procedure with PBS/0.1% Tween 20 (Qbiogene 
Inc, Carlsbad, CA, USA) for 10  minutes. This step was 
omitted for all extracellular stainings. Unspecific bind-
ing sites were blocked by incubation with 5% (v/v) FCS in 
PBS. Staining was achieved by overnight incubation with 
anti- AMPD2 antibody diluted in PBS at 4°C in the dark fol-
lowed by a goat anti- rabbit secondary antibody diluted in 
PBS for two hours at RT. Actin was visualized using TRITC- 
conjugated phalloidin (1:50, Sigma- Aldrich, Cat# P1951, 
RRID:AB_2315148) diluted in PBS/5% FCS for 40 minutes, 
whereas DAPI (1 µg/mL in PBS/5% FCS, 10- minute incuba-
tion) was applied to detect the nuclei. After three 3- minute 
washing steps with PBS images were acquired with an LSM 
880 confocal laser scanning microscope (ZEISS, Germany, 
RRID:SCR_020925) and a Biorevo BZ- 9000 microscope 
(Keyence, RRID:SCR_015486) and analyzed with ZEN 
(ZEISS) and ImageJ.
2.14 | Purine nucleoside measurements
CD14+ monocytes purified by MACS technology were in-
cubated in RPMI without phenol red supplemented with 10% 
(v/v) human AB serum and 1 µg/mL LPS ±1 µg/mL BFA 
as indicated for 24 hours. Supernatants were collected and 
immediately stored at −80°C. Extracellular adenosine levels 
were determined enzymatically with the help of a fluoromet-
ric adenosine assay (abcam, Cat# ab211094) performed ac-
cording to the manufacturer's instructions.
2.15 | Cytokine measurements
PBMCs were cultured in a 24- well plate in RPMI supple-
mented with 10% (v/v) heat- inactivated human AB serum at 
106 cells per well. Incubation with either 100 µM / 1 mM ATP, 
1 µM / 50 µM ADO, 100 µM / 1 mM IMP, or 100 µM / 1 mM 
inosine for 30 minutes was followed by immunostimulation 
with 1 µg/mL LPS for another two hours. Subsequently, su-
pernatants were collected and TNF- alpha release was meas-
ured by ELISA (R&D Systems, Minneapolis, Minnesota, 
Cat# DY210, RRID:AB_2848160).
2.16 | Statistical analysis
Statistical data analysis of mass spectrometric measurements 
was performed using Perseus software (v1.6.2.1). Technical 
and biological replicates for each condition were defined 
as groups and intensity values were filtered for “minimum 
value of 3” per group. After log2 transformation missing val-
ues were imputed with random noise simulating the detec-
tion limit of the mass spectrometer. Imputed values are taken 
from a log normal distribution with 0.25× the standard devia-
tion of the measured, logarithmized values, down- shifted by 
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1.8 standard deviations. Differential protein abundance was 
calculated using two- sample Student's t test, applying a per-
mutation based FDR (false discovery rate) cut- off of 5%.
Statistical analyses of all other samples were performed 
using GraphPad Prism. In order to assess differences between 
paired samples Wilcoxon matched- pairs signed rank test was 
applied. Mann Whitney test was used to compare different 
groups.
2.17 | Search for potential 
membrane domains
UniProt and TMHMM servers were consulted to screen 
AMPD2 for potential transmembrane domains.80,81 
Subsequently, we followed the decision tree suggested by 
HeliQuest: The secondary protein structure was determined 
using the PSIPRED server.82,83 The identified helical regions 
were then submitted to the HeliQuest webserver to calculate 
the hydrophobicity ⟨H⟩, the hydrophobic moment ⟨µH⟩ and 
the net charge z. Based on these data, the discriminant factor D 
was then determined as follows: D = 0.944(⟨µH⟩) + 0.33(z). 
D  >  1.34 defined a lipid- binding helix, while helices with 
0.68  <  D  <  1.34 were classified as possible lipid- binding 
helices.83,84
3 |  RESULTS
3.1 | AMPD2 is differentially expressed in 
primary immune cells and various cell lines 
and is selectively detected on the cell surface
As AMPDs are encoded by three different genes, AMPD1, 
AMPD2, and AMPD3,85 we initially aimed to determine the 
most abundant isoform in human immune cells. Data from 
the Human Protein Atlas reveals that AMPD2 represents 
the most common variant of AMPDs in human leukocytes 
(Figure  2A).86 Consequently, we focused on this isoform 
in the following experiments. In order to identify a suitable 
model system to examine AMPD2 surface expression, we 
first analyzed cytoplasmic AMPD2 expression in different 
cell lines. Flow cytometric analysis following intracellular 
staining showed similar expression levels of AMPD2 in 
all examined cell lines, namely HEK293, HMEC- 1, Jurkat, 
THP- 1, and U- 937 cells (Figure S2A, upper row). Cell lines 
generally displayed low eAMPD2 expression (Figure S2A, 
lower row). However, HEK293 cells and U- 937 presented 
appreciable surface expression (r gMFI  =  2.03 and 2.19) 
and a successful blocking of surface staining by an excess of 
unconjugated antibody and were thus chosen to further ver-
ify the presence of AMPD2 on the cell surface. Western blot 
analysis of AMPD2 immunoprecipitated from HEK293 and 
U- 937 membrane fractions additionally demonstrated the 
localization of AMPD2 in the cell membrane (Figure 2B). 
In order to confirm the identity of the immunoprecipitated 
target protein, mass spectrometric analyses of immunopre-
cipitated samples from HEK293 membrane fractions using 
a mouse monoclonal anti- AMPD2 antibody (QQ13) were 
performed. AMPD2 was found to be the top abundant pro-
tein (TopX) and was significantly enriched compared with 
isotype control (log2(enrichment factor) = 5.82; −log10(P- 
value)  =  3.85 (LFQ)) (Figure  S2C, Table  S1). IP from 
HEK293 whole cell lysates using the staining antibody 
anti- AMPD2 (PA5) was performed in addition in order to 
validate antibody specificity by IP- MS (Table S1).87 By con-
centrating the cytosolic and membrane lysates subsequently 
analyzed by SDS- PAGE, we were able to increase the 
amount of AMPD2 detected on western blot (Figure S2B). 
As our membrane protein purification procedure does not 
explicitly differentiate between plasma membrane and 
subcellular membranes, we conducted further experiments 
to characterize the membrane fraction: we detected both 
lamin B1 and calreticulin— markers of the nuclear mem-
brane and the endoplasmic reticulum, respectively— in the 
purified membrane lysates (Figure  S2D). Contamination 
by cytosolic protein indicated by GAPDH was, however, 
minimal (Figure S2D). As the presence of AMPD2 in the 
membrane fraction is, therefore, not clearly attributable to 
its presence in the plasma membrane, we performed surface 
biotinylation to verify the localization of AMPD2 at the cell 
surface. AMPD2 was detected in biotin- enriched samples 
isolated from HMEC- 1 and U- 937 cells as well as CD14+ 
monocytes by a surface biotinylation assay (Figure 2C). For 
HMEC- 1 cells this result was verified with the help of mass 
spectrometry showing significant enrichment compared 
with non- biotinylated streptavidin- based pull- down controls 
(log2(enrichment factor)  =  3.70; −log10(P- value)  =  2.00 
(LFQ)) (Figure  2D, Table  S2). The top abundant proteins 
enriched by streptavidin- based pull- down following sur-
face biotinylation are listed in Table S2 as proof of efficient 
surface protein enrichment. Figure S2E additionally shows 
flow- through samples to display surface abundance com-
pared with the overall protein content. Surface biotinylation 
was also verified by flow cytometry demonstrating eAMPD2 
expression on surface- biotinylated cells (Figure  S2F). As 
Eltzschig et al previously demonstrated increased surface 
expression of adenosine deaminase in HMEC- 1 cells ex-
posed to hypoxia,88 we additionally evaluated this scenario 
with respect to AMPD2. Interestingly, surface biotinyla-
tion of HMEC- 1 cells cultured under hypoxic conditions 
revealed a slight decrease in AMPD2 surface expression 
(Figure S2G). Mass spectrometric analysis confirmed these 
results (log2(enrichment factor) = −0.44 (LFQ); −log10(P- 
value) = 3.38 (LFQ)). These data corresponded to flow cy-
tometric analyses of the AMPD2 surface staining performed 
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F I G U R E  2  Differential AMPD expression in primary human immune cells and cell lines and detection of AMPD2 in the cell membrane. A, 
mRNA expression of AMPD isoforms in human leukocyte populations according to the Human Protein Atlas.86 The values represent normalized 
expression and were extracted from the Consensus dataset. B, Western blot analysis of AMPD2 pulled down from HEK293 and U- 937 cytosolic 
and membrane fractions by IP using a mouse monoclonal antibody against human AMPD2 (IP AMPD2) compared to isotype control (IP IgG). 
Purity of cytosolic and membrane fractions was verified by analyzing pan Cadherin as well as alpha Tubulin and GAPDH, respectively. Uncropped 
images are provided in Figure S7. C, Western blot analysis of CD14+ monocytes, HMEC- 1 and U- 937 cells after surface protein enrichment. 
Surface biotinylation was performed followed by streptavidin- based pull- down (surface). A non- biotinylated control sample was run in parallel 
(streptavidin). Input samples represent cell lysates after surface biotinylation prior to streptavidin- based enrichment. D, Mass spectrometric analysis 
of surface- enriched protein obtained from HMEC- 1 cells by streptavidin- based pull- down following surface biotinylation. Presence of AMPD2 
in the surface- enriched fraction is displayed compared to streptavidin- based pull- down of non- biotinylated samples (non- biotinylated control) and 
biotinylated whole cell lysate without streptavidin- based pull- down (input), respectively. Differential protein abundance was determined using two- 
sample Student's t test and blue circles represent significance with an FDR cut- off of 5%. E, AMPD2 protein expression was quantified by western 
blot and flow cytometry. Western blot analysis of AMPD2 protein expression in HEK293 and U- 937 whole cell lysates and HEK293 membrane 
fractions after AMPD2 knockdown by lentiviral transduction of shRNA particles and 10- day selection with 1 µg/mL puromycin is shown on 
the left. AMPD2 protein expression was semiquantified relative to beta Actin, pan Cadherin and GAPDH, respectively, by image analysis and 
reduction by shRNA transduction is depicted in relation to a lentiviral negative control vector containing scrambled shRNA. BCA assay was 
utilized for protein quantification of membrane fractions. Uncropped images are provided in Figure S7. Reduced eAMPD2 surface expression in 
HEK293 and U- 937 cells after lentiviral knockdown by shRNA sh3 was reproducible by surface staining and flow cytometric analysis (n = 11- 
12). Doublets and dead cells were excluded for analysis as shown in Figure S1F. The data are depicted as change in r gMFI (geometric mean 
fluorescence intensity of staining to secondary antibody control) in relation to a lentiviral negative control vector containing scrambled shRNA. Bar 
graphs depict median and range. ***P < .001, compared to scrambled shRNA; Wilcoxon matched- pairs signed rank test. WT, wild type; pLKO, 
pLKO.1 puro; scr, scrambled
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in parallel (Figure  S2G). Similarly, changes in CD73 ex-
pression observed under normoxic and hypoxic conditions 
measured by flow cytometry (Figure S2G) were consistent 
with the mass spectrometric analyses (log2(enrichment fac-
tor) = 0.566 (LFQ); −log10(P- value) = 3.96 (LFQ)). In sum-
mary, AMPD2 surface expression was confirmed by three 
independent methods in various cell lines.
3.2 | AMPD2 surface expression is reduced 
after AMPD2 knockdown in HEK293 and U- 
937 cells
In order to further substantiate surface staining specificity 
and verify eAMPD2 expression, we performed AMPD2 
knockdown in HEK293 and U- 937 cells. Knockdown effi-
ciency was examined by transiently transfecting HEK293 
cells with plasmids containing shRNA sequences tar-
geting AMPD2. The corresponding sequences are listed 
in Table  1. Western blot analysis of whole cell lysates 
demonstrated that shRNA constructs 3 and 8 efficiently 
reduced AMPD2 protein expression. Thus, these shRNA 
sequences were used to produce viral particles and sub-
sequently obtain stable gene silencing of AMPD2 by in-
fecting HEK293 and U- 937 cells. Successfully transduced 
cells were selected by puromycin and protein expression 
was analyzed by western blotting of whole cell lysates. 
Image analysis demonstrated that lentiviral knockdown 
with shRNA constructs 3 and 8 reduced AMPD2 protein 
expression by 54% and 33% in HEK293, and by 58% and 
41% in U- 937 cells (Figure 2E). In the following, AMPD2 
protein levels were examined in membrane fractions from 
HEK293 cells stably expressing the viral constructs. 
Western blot analysis revealed that the reduction of 
AMPD2 in the membrane after stable gene silencing was 
similar to the changes observed with respect to the over-
all expression (Figure  2E). This reduction in membrane 
expression was reproduced by flow cytometric analysis 
following surface staining of successfully transduced 
HEK293 and U- 937 cells (Figure 2E).
3.3 | AMPD2 contains lipid- binding 
regions and AMPD2 surface expression is 
reduced by inhibitors of the secretory pathway
After verifying AMPD2 surface expression in different 
cell lines, we screened the proteins for potential membrane 
domains. UniProt and TMHMM servers did not identify 
any transmembrane domains in the protein sequence.80,81 
In order to search for lipid- binding regions that are charac-
teristic of amphitropic proteins— proteins that localize both 
to the cytosol and to the plasma membrane— we identified 
helical regions with the help of the PSIPRED server.82 The 
results of this search are displayed in Figure S2H. A total 
of 143 helical sequences were subsequently submitted to 
the HeliQuest webserver analyzing sequences containing 
18 amino acids at a time in accordance with the server's 
requirements.83 We identified five lipid- binding helices 
and 35 possible lipid- binding helices, although the identi-
fied sequences were overlapping due to the character of 
the search. Therefore, the five lipid- binding helices likely 
form part of one single lipid- binding region. The results 
are shown in Table 2 and Table S3. Additionally, we aimed 
to evaluate possible mechanisms of membrane trafficking 
experimentally: we verified whether changes in eAMPD2 
expression could be provoked by disrupting protein trans-
port via the Golgi apparatus. eAMPD2 expression was 
indeed reduced after treating HEK293 and U- 937 cells 
with either 1 µg/mL BFA or 0.5 µg/mL MN for 24 hours 
(Figure S2I). Thus, we provide evidence that AMPD2 con-
tains lipid- binding regions and that the secretory pathway 
is directly or indirectly involved in membrane trafficking 
of eAMPD2.
3.4 | AMPD2 is expressed on the cell 
surface of peripheral immune cells
Having successfully established a surface staining proce-
dure in HEK293 and U- 937 cells as model systems, we 
were particularly interested in examining its role in primary 
Sequence H µH z D
368NGPIKSFCYRRLQYLSSK385 0.346 0.232 4 1.539008
369GPIKSFCYRRLQYLSSKF386 0.479 0.338 4 1.639072
370PIKSFCYRRLQYLSSKFQ387 0.467 0.346 4 1.646624
371IKSFCYRRLQYLSSKFQM388 0.495 0.329 4 1.630576
372KSFCYRRLQYLSSKFQMH389 0.402 0.248 4 1.554112
Note: Amino acids 368- 389 of the AMPD2 protein sequence: H, µH and z were provided by the HeliQuest 
webserver.83 D was calculated as follows: D = 0.944(⟨µH⟩) + 0.33(z). A lipid- binding helix was defined by 
D > 1.34.
Abbreviations: D, discrimination factor; H, hydrophobicity; z, net charge; µH, hydrophobic moment.
T A B L E  2  Predicted lipid- binding 
region within the AMPD2 protein sequence
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human immune cells. As expression of ectonucleotidases 
CD39 and CD73 has been described in a variety of im-
mune cell populations,4 our first endeavor was to screen 
different leukocyte subsets for eAMPD2 expression. Flow 
cytometric analysis revealed that eAMPD2 was predomi-
nantly expressed on the cell surface of B cells, monocytes 
and granulocytes (Figure  3A). With respect to monocyte 
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between classical, intermediate and non- classical mono-
cytes (Figure S1E). On the other hand, we did not observe 
significant expression of eAMPD2 in the different T cell 
populations examined, namely TH1, TH2, TH17 cells, Tregs 
and CD8+ T cells. Incubation with 25- fold excess uncon-
jugated anti- AMPD2 antibody for 10  minutes completely 
prevented staining of the target protein, thus rebutting the 
possibility of the staining antibody inaccurately adhering to 
the cell surface (Figure S1E). Additionally, eAMPD2 ex-
pression on U- 937 cells and PBMCs was confirmed by im-
munofluorescence microscopy as depicted in Figure 3B and 
Figure S3A. Actin as part of the cytoskeleton was visualized 
with the help of TRITC- conjugated phalloidin, while DAPI 
was applied to detect the cell nuclei. Incubation with rabbit 
IgG isotype control did not result in a signal (Figure S3A), 
whereas a distinct surface staining was achieved by adding 
anti- AMPD2 antibody. Furthermore, membrane fractions 
were prepared from isolated CD14+ monocytes. AMPD2 
was successfully pulled down from the lysates by IP and 
detected by western blotting (Figure  3C). In comparison 
with equivalent samples incubated with corresponding 
isotype controls, AMPD2 was strongly enriched by IP 
performed with anti- AMPD2 antibodies (Figure 3C). The 
comparatively weak signal produced after pull- down with 
the polyclonal antibody “PA5” can be explained by the fact 
that this product is designed for flow cytometry. Significant 
enrichment of AMPD2 by IP from monocytic membrane 
fractions with mouse monoclonal anti- AMPD2 (QQ13) 
compared with isotype control was additionally confirmed 
by mass spectrometry (log2(enrichment factor)  =  4.2; 
−log10(P- value) = 2.87 (LFQ)) (Table S4).
After verifying AMPD2 surface expression in primary 
immune cells and establishing a reliable surface staining, 
we proceeded to examine whether surface expression was 
modifiable by immunostimulation. As we could not refer 
to any previous data regarding eAMPD2 expression, we 
initially incubated PBMCs with 5 µg/mL PHA- L and 1 µg/
mL LPS activating T lymphocytes and monocytes, respec-
tively, and examined the kinetics of eAMPD2 expression 
for 30  hours. While eAMPD2 expression on lymphocytes 
tended to be reduced after incubation with PHA- L, we ob-
served an increase in eAMPD2 on the cell surface of mono-
cytes stimulated with LPS that reached a maximum after 
20- 24 hours (Figure S3E). In contrast, eAMPD2 expression 
was not enhanced in neutrophils activated by LPS stimula-
tion (Figure S3B). Similarly, activating lymphocytes with a 
combination of PMA and ionomycin did not alter eAMPD2 
expression (Figure S3C). Successful T cell stimulation was 
demonstrated by flow cytometric analysis of CD25 and 
CD69 (Figure  S3D). Since we were specifically seeking 
conditions that augmented eAMPD2 expression to under-
stand the role of this enzyme on the cell surface, we fo-
cused on monocytes in PBMC co- culture after 21- 24 hours 
incubation in the following experiments. To guarantee that 
the enhanced surface staining after LPS stimulation was not 
caused by unspecific attachment of staining antibodies to 
dying monocytes upon activation, apoptotic and dead cells 
were excluded by dead cell removal as well as co- staining 
with annexin V. Both procedures did not affect the inten-
sity of eAMPD2 expression measured by flow cytometry 
(Figure S3F). Therefore, we concluded that surface expres-
sion was in fact enhanced distinctively in stimulated mono-
cytes, suggesting a possible role of eAMPD2 as a novel 
pro- or anti- inflammatory switch actively regulated by im-
mune cells in states of inflammation.
3.5 | eAMPD2 and CD39 display a similar 
surface expression pattern
Following this first indication of its relevance, we aimed to 
further understand AMPD2 surface expression in the con-
text of other ectoenzymes. Since we hypothesized a role in 
the ectonucleotidase- driven metabolism of extracellular pu-
rine nucleotides, we initially examined surface expression 
of eAMPD2, CD39 and CD73 by flow cytometry on human 
PBMCs at baseline (Figure  S4A+B). Interestingly, CD73 
was scarcely detectable on monocytes directly after isolation. 
Instead, we observed that CD73 expression was restricted to 
distinct lymphocyte subsets. CD73+ lymphocytes were pre-
dominantly identified as CD8+ T cells and CD19+ B cells 
(Figure  S4D). Similar to eAMPD2, CD39 was predomi-
nantly expressed on monocytes, while only a small fraction 
of lymphocytes was CD39+. Indeed, eAMPD2 expression 
on monocytes tended to correlate with CD39 expression at 
baseline (rSp = 0.6788, P = .0255) (Figure S4B).
F I G U R E  3  AMPD2 surface expression on primary human immune cells. A, Human leukocytes were isolated by red blood cell lysis and 
analyzed for AMPD2 surface expression on different leukocyte subsets by flow cytometry (n = 3). The gating strategy is displayed in Figure S1A. 
ratio gMFI represents the ratio of geometric mean fluorescence intensity of staining to secondary antibody control. B, Localization of AMPD2 on 
the cell surface of U- 937 cells identified by immunofluorescence microscopy. Cells were stained for AMPD2 (green), actin (red) and DAPI (blue). 
The scale bar represents 20 µm. The images show two independent experiments. Extracellular staining for eAMPD2 was performed on intact cells, 
while the cells were permeabilized to achieve intracellular staining. C, Western blot analysis of AMPD2 pulled down from membrane fractions 
of sorted CD14+ monocytes by IP using a mouse monoclonal antibody (QQ13) and a rabbit polyclonal antibody (PA5) against human AMPD2 
compared to isotype control. CD14 was detected as a membrane marker. Uncropped images are provided in Figure S7. Boxplots show median and 
minimum or maximum values, respectively, while bar graphs depict median and range
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3.6 | TLR stimulation enhances AMPD2 
surface expression on monocytes
In order to identify stimuli that enhance eAMPD2 expres-
sion, we next performed toll- like receptor (TLR) stimulation 
at TLRs 1- 9 in PBMC co- culture. Except for Poly (I:C) and 
ODN 2006 that are agonists at TLR3 and TLR9, respectively, 
all reagents significantly enhanced eAMPD2 expression on 
human monocytes. The greatest increase in eAMPD2 expres-
sion compared with the untreated control was observed after 
stimulation of TLR4 and TLR7/8 (Figure 4B). A similar pat-
tern was found regarding CD39 expression on monocytes, 
although agonists of TLR3 and TLR9 effectively enhanced 
CD39 surface expression as well (Figure  4B). Besides a 
slight reduction in CD73 surface expression on monocytes 
after incubation with the TLR9 agonist ODN 2006, CD73 
expression was not significantly affected by TLR activa-
tion (Figure  4B). Lymphocytes were analyzed simultane-
ously and were largely unaffected by TLR stimulation. 
Although a significant reduction in CD73 expression was 
observed for each TLR agonist, these changes were minute 
(Figure  4A). Having confirmed LPS as the strongest trig-
ger of eAMPD2 expression in monocytes, we proceeded to 
examine whether this increase could be prevented by Golgi 
transport inhibition; in order to confirm our prior hypothesis 
that the secretory pathway mediated AMPD2 surface expres-
sion. We observed that concomitant incubation with BFA 
significantly reduced eAMPD2 expression after 24  hours 
compared to LPS alone. This was true for both lympho-
cytes and monocytes in PBMC co- culture (Figure  4C+D). 
CD73 showed similar changes in monocytes, whereas sur-
face expression proved to be more stable in lymphocytes 
(Figure 4C+D). Strikingly, disruption of the Golgi apparatus 
significantly increased monocytic CD39 surface expression 
(Figure  4D). Importantly, these effects were also observed 
for Golgi transport inhibition in the absence of concomitant 
immunostimulation (Figure  4C+D). Incubation with MN 
yielded similar results as BFA (Figure S4E+F). The effects 
observed in PBMC co- culture were successfully reproduced 
in a monoculture of isolated CD14+ monocytes (Figure 4E). 
Simultaneously, membrane fractions were generated from 
CD14+ monocytes and analyzed for AMPD2 protein expres-
sion by western blotting (Figure 4F). In accordance with the 
data acquired by flow cytometry, western blot analysis re-
vealed an increase of approximately 35% in AMPD2 expres-
sion in membrane fractions of CD14+ monocytes stimulated 
with LPS. Of note, analysis of whole cell protein simulta-
neously demonstrated a decrease of total AMPD2 after LPS 
stimulation. Overall, we observed a significant increase in 
eAMPD2 expression on monocytes by TLR activation. This 
effect might either indicate a pro- inflammatory function of 
AMPD2 on the cell surface, maintaining a pro- inflammatory 
environment by impeding adenosine production through 
CD73 in the extracellular space. On the other hand, similar to 
CD39, the upregulation by immunostimulation might equally 
represent a counter- regulatory mechanism to contain the state 
of inflammation.
3.7 | Dexamethasone inversely 
affects AMPD2 surface expression in 
lymphocytes and monocytes
Assuming that the enhancement of eAMPD2 expression by 
TLR agonism in monocytes constitutes a distinct immune 
cell response to immunoactivation, we hypothesized that 
these effects might be attenuated by the application of im-
munomodulatory drugs. First, we examined the impact of 
glucocorticoids (GC) as versatile anti- inflammatory agents 
broadly affecting various immune cell functions.89,90 PBMCs 
were incubated with LPS as before and concomitantly treated 
with either 10−8 M or 10−5 M Dex. Contrary to our expec-
tation, Dex treatment did not significantly prevent the in-
crease in monocytic eAMPD2 expression by LPS stimulation 
(Figure  5A+B). The same was true with respect to CD39. 
However, 10−5  M Dex tended to attenuate the enhance-
ment of eAMPD2 (P = .05). In order to adequately interpret 
these results, we also studied the effects of GC treatment in 
isolation. Flow cytometric analysis revealed that eAMPD2 
expression was not affected by treatment with 10−8 M Dex, 
a concentration that is equivalent to physiological gluco-
corticoid doses.91,92 Notably, incubation with 10−5  M Dex 
(corresponding to high- dose GC therapy)93,94 resulted in a 
significant increase in eAMPD2 expression on monocytes 
while causing the opposite effect in lymphocytes in co- 
culture (Figure S5). A similar pattern was observed analyzing 
CD39 surface expression although the lower Dex concentra-
tion interestingly caused a decrease in CD39 in both popula-
tions. In contrast, CD73 surface expression was uniformly 
reduced by Dex. This effect was stronger in the presence of 
the lower concentration of Dex. Instead of reversing the ef-
fects of immunostimulation on monocytes, incubation with 
high doses of Dex consequently promoted a similar increase 
in the surface expression of both AMPD2 and CD39. We 
thus concluded that this upregulation might indeed represent 
an anti- inflammatory mechanism supported by GC treat-
ment. As the immunomodulatory effects of MTX have been 
described to be partly modulated by changes in ectonucle-
otidase function,95- 97 we exploratorily examined PBMCs 
after incubation with 0.8 µM MTX (corresponding to plasma 
levels achieved by weekly application of 15 mg MTX)98 for 
24 hours in comparison with untreated control samples or in 
the presence of LPS. We found that ectoenzyme expression 
remained unaffected by MTX treatment (Figure 5C+D).
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F I G U R E  4  AMPD2 surface expression 
on human PBMCs is altered by TLR 
stimulation and Golgi transport inhibition. 
Cells were incubated for 21- 24 hours and 
surface expression of eAMPD2, CD39 and 
CD73 was measured by flow cytometry. 
TLR agonism was achieved using 1 µg/mL 
Pam3SCK4 at TLR1/2, 10 µg/mL Poly (I:C) 
at TLR3, 1 µg/mL LPS at TLR4, 100 ng/
mL Flagellin at TLR5, 1 µg/mL FSL- 1 at 
TLR2/6, 1 µg/mL at TLR7/8, and 0.5 µM 
ODN 2006 at TLR9. 1 µg/mL BFA was 
added simultaneously as indicated to inhibit 
Golgi transport. Lymphocytes (A,C) and 
monocytes (B,D) were incubated in co- 
culture and gated according to Figure S1E 
for analysis (n = 7- 8). E, CD14+ monocytes 
were sorted by magnetic cell separation 
and incubated in monoculture (n = 4). 
The applied gating strategy is depicted in 
Figure S1B. ratio gMFI represents the ratio 
of geometric mean fluorescence intensity 
of staining to secondary antibody control. 
F, AMPD2 protein expression in sorted 
CD14+ monocytes was detected by western 
blotting of whole cell lysates and membrane 
fractions after 24- hour incubation with 1 µg/
mL LPS. AMPD2 protein expression was 
semiquantified relative to beta Actin and 
CD14 respectively by image analysis and 
modification by LPS stimulation is depicted 
in relation to a untreated control samples. 
All boxplots show median, interquartile 
range, and minimum or maximum values, 
respectively. *P < .05, **P < .01, compared 
to untreated control; #P < .01, compared to 
























































































































































































































* * * * * *
*
CD73













































































whole cell lysate membrane fraction
donor A donor B




   | 15 of 25EHLERS Et aL.
3.8 | Patients with rheumatoid arthritis 
show increased AMPD2 surface expression in 
peripheral blood lymphocytes and monocytes
Having confirmed that eAMPD2 expression was distinctively 
modified by immunoactivation in vitro, we investigated 
whether eAMPD2 was equally affected by inflammatory 
conditions in vivo. Therefore, we isolated PBMCs from pe-
ripheral blood samples from patients with RA and healthy 
controls. Patient characteristics are provided in Table 3. The 
majority of patients were under immunosuppressive therapy. 
Sex and age distribution in the healthy control group did not 
differ significantly from the patient group (Table 3). Surface 
expression of AMPD2, CD39 and CD73 was examined by 
flow cytometry. Comparing PBMCs at baseline, we ob-
served that eAMPD2 expression in RA patients was signifi-
cantly elevated compared with healthy controls (Figure 6A). 
Remarkably, this was true for both lymphocytes and mono-
cytes. This enhancement did not correlate with CRP levels 
indicating inflammatory activity nor with the current GC 
dose, although a reliable correlation analysis would require 
a greater sample size. Contrary to our previous results, 
CD39 expression in monocytes was not correspondent with 
eAMPD2 in this experiment where no differences between 
RA patients and healthy controls were apparent (Figure 6A). 
Lymphocytes, on the other hand, showed significantly lower 
levels of CD39 expression (Figure 6A) although the overall 
expression was low and lymphocyte subsets would have to 
be analyzed separately to properly evaluate the relevance of 
this finding. CD73 expression was not significantly differ-
ent between the two groups (Figure 6A). Regarding CD73, 
we found that monocytic expression was generally very low 
at baseline immediately after isolation and increased in cell 
culture. These findings are discussed more thoroughly in the 
Appendix.
After confirming differences in baseline expression of 
eAMPD2, we were interested whether expression patterns in 
PBMCs from RA patients also differed from healthy controls 
F I G U R E  5  AMPD2 surface expression on human PBMCs following immunomodulation. Cells were incubated for 21- 24 hours and surface 
expression of eAMPD2, CD39 and CD73 was measured by flow cytometry. Lymphocytes (A,C) and monocytes (B,D) were incubated in co- 
culture and gated according to Figure S1E for analysis. ratio gMFI represents the ratio of geometric mean fluorescence intensity of staining to 
secondary antibody control. A,B, PBMCs were treated with 1 µg/mL LPS ± 10−8 and 10−5 M dexamethasone, respectively (n = 8). C,D, PBMC co- 
cultures were incubated with 0.8 µM methotrexate and 1 µg/mL LPS, respectively, and a combination of both (n = 2). All boxplots show median, 
interquartile range, and minimum or maximum values, respectively. *P < .05, **P < .01, compared to untreated control; #P < .01, compared to 
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in response to in vitro stimulation. Cells were incubated with 
LPS as before and surface expression of AMPD2, CD39 
and CD73 was assessed by flow cytometry after 24 hours. 
Overall, the response to LPS in PBMCs from RA patients 
resembled that of healthy controls (Figure  6B). However, 
contrary to corresponding samples from healthy controls, 
several patients did not exhibit an increase in monocytic sur-
face expression of AMPD2 (P = .14) and CD39 (P = .05). 
With respect to eAMPD2, we concluded that elevated surface 
expression in monocytes at baseline represents a counter- 
regulatory mechanism in response to the inflammatory state 
prevalent in RA. We assumed that this permanent upregu-
lation impedes any further increase in eAMPD2 expression 
upon in vitro stimulation. While changes in CD73 expression 
did not differ between stimulated monocytes from healthy 
controls and RA patients, we did nevertheless observe a strik-
ing difference compared with the expression pattern in our 
previous measurements where LPS stimulation generally in-
creased monocytic CD73 expression (Figure 4D). Comparing 
the characteristics of healthy donors in these experiments, it 
became evident that the age distribution was significantly dif-
ferent between the two groups (P = .003). For this reason, we 
reanalyzed our data by dividing the healthy donors into two 
groups (≤40 years and ≥50 years) (Table S5). Interestingly, 
we found that ectoenzyme expression in monocytes stimu-
lated with LPS was indeed regulated significantly differently 
in young and old donors (Figure S6B). In comparison with 
the younger group, monocytes from older individuals showed 
a significantly weaker upregulation of AMPD2, CD39 and 
CD73 surface expression. Differences between the two 
groups were also apparent at baseline (Figure S6A).
In conclusion, our data showed that eAMPD2 was dif-
ferentially regulated in both RA and aging— two states as-
sociated with distinct patterns of inflammation. We thus 
concluded that eAMPD2 might indeed exert an immunoreg-
ulatory function by modifying the extracellular balance of 
purine metabolites.
3.9 | Increased AMPD2 surface 
expression does not prevent extracellular 
adenosine production
According to our initial hypothesis, we assumed that 
eAMPD2 might in fact exhibit either a pro- inflammatory or 
an anti- inflammatory role in the extracellular space. By me-
tabolizing AMP to IMP, the deaminase processes the product 
of CD39 action, thereby shifting the balance of this reaction 
and enabling further degradation of ATP by the ectonucleoti-
dase. This reduction of pro- inflammatory ATP favors a pre-
dominantly anti- inflammatory role of surface AMPD2. On 
the other hand, AMP also represents the substrate of ADO 
generation by CD73. AMP depletion by AMPD2 might 
therefore equally cause a reduction in eADO— a very potent 
anti- inflammatory molecule.56 In order to evaluate the likeli-
hood of either scenario, we isolated CD14+ monocytes from 
PBMCs by magnetic cell separation and incubated the cells 
with 1 µg/mL LPS ±1 µg/mL BFA for 24 hours. Supernatants 
were collected after 24  hours and surface expression of 
eAMPD2, CD39 and CD73 was determined by flow cytom-
etry (Figure 4E). Fluorometric measurements of ADO in the 
supernatant revealed that an increase in eAMPD2 expression 
was not associated with a decrease in eADO (Figure  6C). 
In contrast, stimulation with LPS demonstrated maximal 
eAMPD2 expression (Figure  4E) and the highest levels of 
ADO in the supernatant (Figure 6C). CD73 expression was 
also at the maximum under these conditions and certainly 
contributed to the increase in eADO production. Similarly, a 
decrease in the ecto- 5′- nucleotidase was presumably respon-
sible for the reduction in eADO observed after Golgi trans-
port inhibition. Moreover, immune cell activation and death 
considerably affect extracellular purine metabolite levels so 
that immunostimulation might cause changes in eADO levels 
independent of ectoenzyme expression.9,16,18,19,99 However, 
the percentage of dead cells did not differ between cells 
stimulated with LPS only or a combination of LPS and BFA. 
While this assay is consequently not suitable to exclusively 
measure eAMPD2 action, the results nevertheless refute the 
hypothesis that enhanced expression of eAMPD2 on the cell 
T A B L E  3  Patient characteristics
Patients, n 15
Healthy controls 13
Female, n (%) 11 (73)
Healthy controls 8 (62)
Age [years], median (IQR) 61 (54- 73)
Healthy controls 56 (51- 75)
Disease duration [years], median (IQR) 17 (8.5- 32)
RF- positive, n (%) 10 (67)
Anti- CCP- positive, n (%) 10 (67)
CRP [mg/L], median (IQR) 5 (1.1- 6.5)a 
ESR 1st hour [mm/h], median (IQR) 18 (9.5- 35)b 
SJC [n/28], median (IQR) 2 (0.5- 3.5)b 
TJC [n/28], median (IQR) 1 (0- 4.5)b 
Receiving DMARDs, n (%) 12 (80)
Receiving GCs, n (%) 11 (73)
Current GC dose [mg/d PE], median (IQR) 5 (3- 10)c 
Abbreviations: CCP, cyclic citrullinated peptide; CRP, C- reactive protein; 
DMARDs, disease- modifying anti- rheumatic drugs; ESR, erythrocyte 
sedimentation rate; GC, glucocorticoids; IQR, interquartile range; PE, 
prednisone equivalent; RF, rheumatoid factor; SJC, swollen joint count; TJC, 
tender joint count.
aInformation available for 12/15.
bInformation available for 9/15.
cCalculated only for patients receiving glucocorticoids.
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F I G U R E  6  eAMPD2 expression on PBMCs from RA patients and functional assays suggest an anti- inflammatory potential of AMPD2 
surface expression. A, eAMPD2, CD39 and CD73 surface expression was analyzed by flow cytometry directly after isolation (n = 12). PBMCs 
were gated according to Figure S1E for analysis. ratio gMFI represents the ratio of geometric mean fluorescence intensity of staining to secondary 
antibody control. B, Flow cytometric analysis of eAMPD2, CD39 and CD73 surface expression after incubation with 1 µg/mL LPS for 21- 24 hours 
in co- culture (n = 10). PBMCs were gated according to Figure S1E for analysis. Modification by LPS stimulation is depicted in relation to 
untreated control samples. C, CD14+ monocytes were purified from human PBMCs by MACS technology and incubated with 1 µg/mL LPS ±1 µg/
mL BFA for 24 hours. The concentration of adenosine in the supernatant was determined using a fluorometric assay (n = 2). D, TNF- alpha release 
determined by ELISA. PBMCs were preincubated with 100 µM IMP for 30 minutes, 1 µg/mL LPS was added for another 2 hours (n = 6). Lines 
on scatter dot plot represent median. Boxplots show median, interquartile range, and minimum or maximum values, respectively. *P < .05, Mann 
Whitney test (A+B) and Wilcoxon matched- pairs signed rank test (C+D). IMP, inosine 5′- monophosphate
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surface prevents production of anti- inflammatory ADO in the 
extracellular space.
3.10 | Inosine monophosphate— the 
product of AMPD2 action— exerts anti- 
inflammatory effects
In the system of extracellular purine metabolism regulated 
by the ectonucleotidases CD39 and CD73, the element that 
is newly introduced by the discovery of AMPD2 surface 
expression is the extracellular production of IMP. While 
the role of eATP and eADO has been studied in detail, the 
function of inosine derivatives in the interstitial space is less 
certain.6,13,56,100,101 For this reason, we aimed to examine the 
potential of excess extracellular IMP in balancing inflam-
mation. PBMCs were primed with low and high supraphysi-
ological concentrations of different purine metabolites and 
subsequently stimulated with 1 µg/mL LPS for two hours. 
Purine metabolites were applied at concentrations detected 
in the extracellular space under inflammatory conditions 
as described previously.102- 111 The ADO concentrations 
applied also corresponded with the levels measured in our 
own experiments in the supernatant of cultured immune 
cells (Figure  6C). TNF- alpha was measured in the super-
natants as an indicator of inflammatory activity. Prior incu-
bation with 100 µM IMP significantly reduced TNF- alpha 
release from PBMCs after LPS stimulation (Figure 6D). We 
therefore concluded that eAMPD2 exerts anti- inflammatory 
effects by production of extracellular IMP and is upregu-
lated upon immunoactivation to contain the inflammatory 
environment. As expected, ADO also exhibited highly ef-
ficient anti- inflammatory activity (P  =  .03). In compari-
son, inosine was less potent in reducing TNF- alpha release 
(P  =  .22). Surprisingly, ATP resulted in the strongest de-
crease in TNF- alpha release (P = .03). This effect was con-
trary to the pro- inflammatory activity usually attributed to 
eATP.102 Considering the ample expression of ectoenzymes 
in PBMCs, this finding can nevertheless be accounted for by 
an increase in ADO and IMP production by supplying ATP 
as a substrate.
4 |  DISCUSSION
In this study, we verified AMPD2 surface expression in 
primary human immune cells and assessed differences in 
expression in patients with RA. Through a combination of 
mass spectrometry from membrane fractions and surface 
staining procedures, we identified eAMPD2 as a novel ec-
toenzyme involved in the extracellular purine metabolism. 
Immunostimulation increased monocytic eAMPD2 expres-
sion and RA patients exhibited higher surface expression 
levels at baseline. This upregulation was not associated with 
a decrease in eADO levels in cell culture, while IMP exerted 
anti- inflammatory effects on immune cells.
By confirming AMPD2 surface expression in immune 
cells, we pursued a concept that was first discussed over 
50 years ago in muscle tissue.63,64 Contrary to Rao and Pipoly 
who described attachment of AMPD to the inner erythrocyte 
membrane,65,66 we found that AMPD2 is indeed expressed on 
the outer surface and consequently potentially relevant to the 
extracellular milieu. While CD39 and CD73 are integrated 
into the plasma membrane by transmembrane domains and 
a GPI anchor, respectively,112,113 UniProt and TMHMM que-
ries revealed no corresponding motifs in the AMPD2 pro-
tein sequence.80,81 In order to further elucidate membrane 
trafficking of eAMPD2, we analyzed surface expression 
after Golgi transport inhibition and observed a significant 
reduction suggesting involvement of the secretory pathway 
in the surface localization of eAMPD2. These results are in 
line with previous data locating AMPD in subcellular mem-
brane fractions.114,115 Sims et al identified pleckstrin homol-
ogy domains that might mediate membrane- association via 
phosphoinositide binding in both AMPD2 and AMPD3.116 
Similarly, our search identified a lipid- binding region in the 
AMPD2 protein sequence. These helical domains are char-
acteristic of amphitropic proteins— a class first described by 
Burn in 1988.84,117 This group of cytosolic proteins displays 
structural features that enable a reversible interaction with 
the plasma membrane.118,119 The presence of a lipid- binding 
helix therefore represents a potential mechanism permitting 
eAMPD2 to associate with the membrane. Further work will 
be needed to understand this process in detail.
Since the expression pattern of CD39 and CD73 differs 
between immune cell subsets, we determined eAMPD2 ex-
pression in various leukocyte populations.4 We found that 
eAMPD2 expression intensities resembled the distribution 
of CD39 described previously. These findings suggest that 
eAMPD2 might assist CD39 activity by shifting the ATP:AMP 
ratio and hence promoting hydrolysis of pro- inflammatory 
ATP by CD39. This theory is further supported by the fact 
that monocytic eAMPD2 expression correlated with CD39. 
Similarly, we observed an upregulation in both eAMPD2 and 
CD39 in monocytes upon TLR stimulation. According to our 
hypothesis, this upregulation under inflammatory conditions 
might be beneficial by containing ATP signaling and thereby 
attenuating a potentially detrimental inflammatory response. 
In accordance with this concept, CD39 deficient mice exhib-
ited increased levels of vascular inflammation.120 Conversely, 
transducing fibroblast- like synoviocytes with CD39 and 
CD73 resulted in reduced secretion of pro- inflammatory 
cytokines.121 Moreover, an induction of AMPD2 had been 
previously described in chondrocytes upon exposure to IL- 
1β.122 Since these changes in overall AMPD2 protein expres-
sion were reversed by incubation with immunomodulatory 
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agents, we evaluated whether eAMPD2 upregulation was 
also mitigated by anti- inflammatory therapeutics. Although 
Dex slightly attenuated the increase in eAMPD2 expression 
in monocytes upon stimulation with LPS, these changes were 
however not significant. Interestingly, exposure to therapeu-
tic concentrations of Dex alone significantly increased mono-
cytic eAMPD2 expression. We concluded that eAMPD2 
upregulation might thus mediate anti- inflammatory effects of 
Dex in the extracellular space. Indeed, AMPD2 and AMPD3 
have previously been recognized as genes addressed by glu-
cocorticoid receptor signaling.123,124 The discrepant effects 
of Dex on monocytic eAMPD2 expression observed in the 
presence and absence of concomitant immunostimulation 
might reflect the attenuation of the inflammatory stimuli 
in the first scenario as opposed to the direct impact of Dex 
on AMPD2 surface expression in the latter. A reduction in 
eAMPD2, CD39 and CD73 expression was observed in the 
lymphocyte population. In contrast, previous studies of spe-
cific lymphocyte subsets demonstrated an increase in both 
CD39 and CD73 expression caused by Dex treatment.125- 128 
Likewise, the mechanism of action of MTX has been at-
tributed to changes in AMPD activity.129,130 However, con-
trary to Dex, the anti- inflammatory effect in this context is 
not ascribed to a facilitation of ATP degradation, but rather to 
an inhibition of AMPD causing increased levels of eADO.95 
Correspondingly, polymorphisms causing reduced AMPD 
activity were associated with enhanced responsiveness to 
MTX, while low CD39 expression in Tregs caused the op-
posite.131,132 Bossennec et al found that MTX treatment was 
indeed associated with increased ADO production by TH 
cells from RA patients.96 Nevertheless, we did not observe 
changes in eAMPD2 expression after incubation with MTX. 
Importantly, it has to be considered that— in vivo— several 
immunomodulatory effects only manifest after up to three 
months of MTX therapy.133 Also, the proposed mechanism 
of MTX action only refers to cytosolic AMPD activity. While 
we focused on eAMPD2 expression, it would be desirable to 
perform analyses of eAMPD2 function under MTX treatment 
in the future.
Differences in ectonucleotidase expression have been 
observed in various immune- mediated diseases. On the one 
hand, an elevated expression of CD39, CD73 and A2AR, re-
spectively, has been described in neutrophils and monocytes 
from the synovial fluid of mice with collagen- induced ar-
thritis and the peripheral blood of patients with uveitis.38,51 
Also, FOXP3+CD39+ Tregs were found to be enriched in 
the synovial tissue of RA patients.134 On the other hand, de-
creased expression of CD39, A1R and A2BR was detected 
in patients with ankylosing spondylitis and CD73 was down-
regulated on Tregs from psoriasis patients.49,50 Likewise, a 
reduction in ADO formation was observed in the synovial 
fluid of patients with juvenile idiopathic arthritis.48 These 
diverging results indicate both a potential dysregulation of 
ectonucleotidase expression enhancing inflammation by 
impaired eADO production and a counter- regulatory in-
crease in CD39 and CD73 expression to attenuate the pro- 
inflammatory response in autoimmune diseases. Compared 
with sex- and age- matched healthy controls we observed 
higher levels of eAMPD2 expression in both lymphocytes 
and monocytes from RA patients. Interestingly, monocytic 
CD39 expression did not differ in our cohort. In response to 
TLR4 stimulation, upregulation of eAMPD2 in monocytes 
was not significantly different in the two groups, although 
it tended to be lower in RA patients. This is in line with the 
increased baseline levels, preventing further upregulation 
following a pro- inflammatory stimulus. As stated before, 
increased levels of eAMPD2 expression might constitute a 
counter- regulatory mechanism, promoting the removal of im-
munostimulatory ATP and providing anti- inflammatory IMP. 
AMPD activity has indeed been shown to correlate inversely 
with ATP levels.135- 137 Importantly, our RA cohort comprises 
a diverse population that does not allow for the differential 
assessment of the impact of disease activity and current im-
munosuppressive therapy. Similarly, further experiments will 
be necessary to determine the relevance of the age- related 
differences observed in our cohort and ensure that the results 
were not caused by confounding factors like comorbidities. 
On the other hand, eAMPD2 may equally represent an am-
biguous mediator of the extracellular ATP- adenosine balance 
by simultaneously reducing AMP supply and thereby impair-
ing eADO generation. In fact, contrary to our findings in RA 
patients, Guo et al detected decreased overall AMPD2 pro-
tein levels in SLE patients.138
Consequently, we aimed to evaluate whether modifying 
eAMPD2 expression was indeed associated with changes 
in extracellular eADO content. We did not observe a reduc-
tion in eADO concentrations under conditions of increased 
eAMPD2 expression. Thus, we concluded that impairing 
anti- inflammatory ectonucleotidase function does not seem 
to be the dominant role of eAMPD2. However, our approach 
only represents an approximation of eAMPD2 activity and 
does not exclude the action of other ectoenzymes present in 
the experimental setup. A more precise analysis of eAMPD2 
function will be advantageous to define the exact role of 
eAMPD2 in the extracellular purine metabolism: direct 
measurements of extracellular AMP and IMP levels and the 
use of specific inhibitors will be necessary to characterize 
the enzymatic function on the cell surface. In order to pro-
vide an initial concept of the immunoregulatory capacity of 
extracellular AMP deamination, we exploratorily examined 
the anti- inflammatory effects of IMP and inosine in com-
parison to adenine nucleot(s)ides. IMP was indeed capable 
of reducing TNF- alpha secretion from PBMCs upon TLR4 
stimulation, supporting the immunomodulatory potential of 
extracellular AMPD2 activity. Our results are in agreement 
with previous findings highlighting the anti- inflammatory 
20 of 25 |   EHLERS Et aL.
potency of inosine. Inosine has been shown to signal via 
ADO receptors.111,139- 141 Immunosuppressive effects of 
inosine have been observed in multiple leukocyte popula-
tions including T cells, monocytes, neutrophils and macro-
phages.109,142,143 Moreover, Qiu et al demonstrated that IMP 
exhibited anti- inflammatory potential by inhibiting neu-
trophil accumulation.144 The additional benefit of inosine 
derivatives in the extracellular space might consist in their 
longevity. Compared with the very short- lived ADO (half- 
life: 10  seconds), the half- life of inosine has been defined 
as 15 hours.145,146 While ADO might serve as an immediate 
regulator with strong anti- inflammatory potential, inosine 
nucleotides might permit a more prolonged modulation of 
the inflammatory environment.
In conclusion, we provide evidence of AMPD2 surface 
expression in human primary immune cells for the first time 
and thereby introduce a novel regulator of the extracellular 
purine metabolism that is differentially regulated under in-
flammatory conditions. We propose that an upregulation of 
eAMPD2 might enhance the removal of pro- inflammatory 
ATP from the extracellular space, although further work 
will be required to elucidate the precise function of this 
novel ectoenzyme in the inflammatory microenvironment. 
Considering the promising role of therapeutic agents in ad-
vancing the treatment of both immune- mediated and on-
cological diseases, we regard our findings as an important 
advancement expanding the system of immunoregulatory 
ectonucleotidases.
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APPENDIX 
Monocytic expression of CD73 is dependent on cell cul-
ture conditions
Besides our main findings, we observed a strong increase in 
monocytic CD73 expression during cell culture. Interestingly, 
this effect was only observed in cultures containing human 
serum while CD73 expression remained low in monocytes 
cultured in medium supplemented with FCS (Appendix 
Figure A1). As a marked expression of CD73 has been de-
scribed as a characteristic feature of M2 macrophages, we 
hypothesised that the presence of human serum promoted 
monocyte adhesion and thereby differentiation towards a mac-
rophage phenotype.1- 3 As a side note, CD73 was also consid-
erably upregulated in THP- 1 cells incubated with PMA. While 
this activation was likewise associated with cell adhesion even 
in the absence of human serum, the cells remained in suspen-
sion upon stimulation with LPS and did not show an upregula-
tion of CD73 under these conditions (Appendix Figure A2). 
The abundance of CD73 in macrophages as a tissue- resident 
cell type is consistent with the fact that adenosine as the prod-
uct of this ectonucleotidase has a very short half- life in com-
parison with other purine metabolites.4,5 Its action is therefore 
confined to its production site, which is in accordance with the 
low expression of CD73 in circulating monocytes.
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FIGURE A1 PBMCs were co- cultured in RPMI supplemented with 
either FCS or human AB serum for 24 hours. Monocytic CD73 surface 
expression was determined by flow cytometry. Monocytes were gated 
according to Supplementary Figure S1E for analysis. Lines on scatter 






















F I G U R E  A 2  Flow cytometric analysis of CD73 surface 
expression on THP- 1 cells stimulated with 1 μg/mL LPS or 10 ng/
mL PMA for 24 hours. Cells were gated according to Supplementary 
Figure S1F for analysis.
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